Lewis Rubin
Professor of Pediatrics · MedStar Health Georgetown University
Credentials: · · · · ·
History
- 1985–1988
Neonatal-Perinatal Medicine
- 1982–1985
Pediatrics
1978–1982
Research
Variations in prevalence of hypotension, hypertension, and vasopressor use in NICUs
Journal of Perinatology · 2001 · 142 citations
American Journal of Physiology-Lung Cellular and Molecular Physiology · 2002 · Last of 6 authors · 118 citations
Metabolic Effects of Inflammation on Vitamin A and Carotenoids in Humans and Animal Models
Review · Advances in Nutrition · 2017 · First of 5 authors · 107 citations
- JS
6 papers · 2 as a fellow
- MP
6 papers
- BS
4 papers
4 papers
- JP
4 papers
- EB
3 papers
- FB
3 papers
- IF
3 papers
Grants
- 2002–2008
Placental Carotenoids: Metabolism and Development
National Institute of Child Health and Human Development · R01
Contact PI · $1.4M · Cleveland Clinic Lerner Com-Cwru
- 1997–2002
Biological Basis for Perinatal Transition
National Institute of Child Health and Human Development · P01
Project lead · $770.8K · Women and Infants Hospital-Rhode Island
- 1993–1998
Vascular Disease Academic Award, Nhlbi
National Heart, Lung, and Blood Institute · K07
Contact PI · $706.5K · University of Maryland Baltimore
- 1988–1991
Characterization of Fetoplacental Pth-Like Factors
National Institute of Child Health and Human Development · K08
Contact PI · $194K · Women and Infants Hospital-Rhode Island
Clinical trials
- 2006–2009
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
Principal investigator · Completed · Phase 3
Gilead Sciences
- 2002–2003
Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
Principal investigator · Completed · Phase 2
Gilead Sciences
- 2009–2011
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
Study chair · Completed · Phase 3
United Therapeutics
- 2004–2006
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
Study chair · Completed · Phase 3
Gilead Sciences